HT-ALZ emerges as a promising novel solution for combating
neuroinflammation and cognitive deficits associated with
Alzheimer's Disease.
NEW
YORK, March 19, 2024 /PRNewswire/ -- Hoth
Therapeutics, Inc. (NASDAQ: HOTH), is pleased to unveil positive
pre-clinical research showcasing the potential of HT-ALZ, an
innovative Alzheimer's disease therapeutic. Targeting the Substance
P/Neurokinin 1 Receptor pathway, HT-ALZ emerges as a promising
novel solution for combating neuroinflammation and cognitive
deficits associated with Alzheimer's Disease.
This pioneering study, conducted by a distinguished team of
researchers including Carla Yuede,
Kate M. Reardon, Ryan T. Harrigan, and John R. Cirrito, among others, highlights
HT-ALZ's profound impact on Alzheimer's pathology. By specifically
antagonizing the NK1 receptor, HT-ALZ not only reduces soluble Aβ
levels in the brain's interstitial fluid but also significantly
diminishes anxiety-like behavior and enhances cognitive function in
preclinical models.
The research presents compelling evidence of HT-ALZ's capacity
to improve memory tasks related to the hippocampus and sensorimotor
gating, showcasing an important step forward in Alzheimer's disease
treatment. While the effects on plaque deposition and Aβ levels
were inconclusive, the treatment's cognitive benefits suggest that
HT-ALZ's mode of action may involve a reduction in brain
inflammation, thereby improving cognitive outcomes for Alzheimer's
patients.
HT-ALZ's pre-clinical significance lies in its ability to
restore cognitive functions and improve quality of life for
subjects suffering from Alzheimer's disease, offering a beacon of
hope.
Hoth Therapeutics remains committed to further research and
development of HT-ALZ, including detailed analyses of its effects
on microglial activation and brain inflammation. The company is
optimistic about HT-ALZ's path toward. The full manuscript of the
study will be published later this year and we look forward to a
presentation of the results by the scientists named above who will
be sharing this data at an Alzheimer's Research Center group at
Washington University in St Louis.
For more information on Hoth Therapeutics and our innovative
approach to Alzheimer's disease treatment with HT-ALZ, please visit
https://hoththerapeutics.com
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company
dedicated to developing innovative, impactful, and ground-breaking
treatments with a goal to improve patient quality of life. We are a
catalyst in early-stage pharmaceutical research and development,
elevating drugs from the bench to pre-clinical and clinical
testing. Utilizing a patient-centric approach, we collaborate and
partner with a team of scientists, clinicians, and key opinion
leaders to seek out and investigate therapeutics that hold immense
potential to create breakthroughs and diversify treatment options.
To learn more, please visit
https://ir.hoththerapeutics.com/ .
Forward-Looking Statement
This press release includes forward-looking statements based
upon Hoth's current expectations, which may constitute
forward-looking statements for the purposes of the safe harbor
provisions under the Private Securities Litigation Reform Act of
1995 and other federal securities laws, and are subject to
substantial risks, uncertainties, and assumptions. These statements
concern Hoth's business strategies; the timing of regulatory
submissions; the ability to obtain and maintain regulatory approval
of existing product candidates and any other product candidates we
may develop, and the labeling under any approval we may obtain; the
timing and costs of clinical trials, and the timing and costs of
other expenses; market acceptance of our products; the ultimate
impact of the current coronavirus pandemic, or any other health
epidemic, on our business, our clinical trials, our research
programs, healthcare systems, or the global economy as a whole; our
intellectual property; our reliance on third-party organizations;
our competitive position; our industry environment; our anticipated
financial and operating results, including anticipated sources of
revenues; our assumptions regarding the size of the available
market, benefits of our products, product pricing, and timing of
product launches; management's expectation with respect to future
acquisitions; statements regarding our goals, intentions, plans,
and expectations, including the introduction of new products and
markets; and our cash needs and financing plans. There are a number
of factors that could cause actual events to differ materially from
those indicated by such forward-looking statements. You should not
place reliance on these forward-looking statements, which include
words such as "could," "believe," "anticipate," "intend,"
"estimate," "expect," "may," "continue," "predict," "potential,"
"project" or similar terms, variations of such terms, or the
negative of those terms. Although the Company believes that the
expectations reflected in the forward-looking statements are
reasonable, the Company cannot guarantee such outcomes. Hoth may
not realize its expectations, and its beliefs may not prove
correct. Actual results may differ materially from those indicated
by these forward-looking statements as a result of various
important factors, including, without limitation, market conditions
and the factors described in the section titled "Risk Factors" in
Hoth's most recent Annual Report on Form 10-K and Hoth's other
filings made with the U. S. Securities and Exchange Commission. All
such statements speak only as of the date made. Consequently,
forward-looking statements should be regarded solely as Hoth's
current plans, estimates, and beliefs. Investors should not place
undue reliance on forward-looking statements. Hoth cannot guarantee
future results, events, levels of activity, performance, or
achievements. Hoth does not undertake and specifically declines any
obligation to update, republish, or revise any forward-looking
statements to reflect new information, future events, or
circumstances or to reflect the occurrences of unanticipated
events, except as may be required by applicable law.
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download
multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-announces-positive-data-in-completed-study-of-alzheimers-disease-pre-clinical-treatment-with-ht-alz-302092476.html
SOURCE Hoth Therapeutics, Inc.